February 7th 2025
This combination antibiotic is indicated for adults with limited or no treatment options, including gram-negative infections. It will be available in the third quarter of this year.
Updated Guidelines Look to Reduce Hospital-Acquired MRSA
July 1st 2023Five organizations have updated the 2014 compendium, "Strategies to Prevent Methicillin-Resistant Staphylococcus aureus Transmission and Infection in Acute Care Hospitals." In doing so, they have elevated antimicrobial stewardship from an “additional practice” to an “essential practice.”
Read More
Free, Open Source Tool Harnesses EHR Data to Assess, Improve Antibiotic Prescribing
June 28th 2023The Outpatient Automated Stewardship Information System (OASIS) is a platform that allows clinicians the ability to improve their prescribing practices in hopes of delivering a more judicious approach and moving towards stewardship.
Watch
Continuous, Intermittent Administration of Meropenem for Sepsis Yield Similar Outcomes
June 28th 2023The strategy for administering beta-lactam antibiotics for treating critically ill patients with sepsis showed no clinical difference in a study of continuous versus intermittent administration of meropenem.
Read More
Pfizer Investigational Antibiotic Combination Demonstrates Efficacy Against Gram-Negative Infections
June 14th 2023In phase 3 studies, the company’s investigational therapy, aztreonam-avibactam (ATM-AVI), had favorable results over other treatments used for complicated intra-abdominal infections (cIAI), hospital-acquired pneumonia (HAP), and ventilator-associated pneumonia (VAP).
Read More
Challenging the Status Quo: Oral Transitional Therapy for Infective Endocarditis
June 8th 2023New evidence suggests that oral transitional therapy may be a promising option for the treatment of infective endocarditis (IE). A retrospective cohort study reveals comparable clinical outcomes between oral and intravenous antibiotic regimens.
Read More
The innovative antibiotic Xacduro has received FDA approval for its efficacy against ventilator-associated bacterial pneumonia caused by Acinetobacter baumannii-calcoaceticus. The intravenous therapy combines sulbactam and durlobactamto target multidrug-resistant and carbapenem-resistant strains.
Read More
FDA Approves Sulbactam-Durlobactam for Bacterial Pneumonia
May 23rd 2023The antibiotic, marketed as Xacduro, is indicated for hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) caused by susceptible strains of bacteria called Acinetobacter baumannii.
Read More
Preparing for AUR Reporting Mandates to Capitalize on Quality Reimbursement
May 15th 2023The mandatory reporting of Antimicrobial Use and Resistance (AUR) by hospitals participating in the CMS Medicare Promoting Interoperability Program beginning next year is a important strategy in curbing the overuse of antibiotics.
Read More